Crucell selects Runbook for Fast Close in SAP
Ede, 13th April 2010
Crucell, the biopharmaceutical company, will use Runbook's financial process automation, compliance and control software to standardize and automate its month-end close process when it goes live with its SAP ERP system later this month.
Crucell had already chosen SAP as its ERP system. According to Peter Verhoeve, Business Development Manager at Runbook Company, Crucell's objective was to implement at the same time a solution to automate and streamline its close process.
After looking at competing solutions Runbook was chosen because of the seamless integration with SAP, its user-friendly interface and the company's deep knowledge and expertise with SAP and the fast close process. In addition, Runbook supports Crucell's need to build up a digital audit trail and automate internal controls as much as possible in order to eliminate risk.
Herman Heller, CEO of Runbook Company, commented: "We are delighted to add yet another pharmaceutical business to our growing list of global clients seeking to accelerate and control their close cycle based on SAP ERP."
About Runbook Company International
Runbook Company is the world's leading provider of financial software with solutions that streamline the financial close, internal controls and compliance documentation processes in SAP. Organizations who have implemented Runbook have been able to successfully reduce cost and improve quality through the automation of recurring financial processes. Understanding the unique aspects of financial processes, Runbook Company provides solutions which automate and streamline these processes resulting in improved efficiency, visibility and transparency in critical areas.
Runbook clients include Adidas, Akzo Nobel, Alliander, Deloitte, DSM, Dutch Ministery of Defense, Heineken, Novartis, NXP, Océ, Philips, Procter & Gamble, Sabic Europe, Sandoz, Shell and Wolters Kluwer. Runbook Company is a certified SAP Software Partner.
About Crucell
Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. Crucell focuses on the reasearch & development, production and marketing of vaccines and antibodies against infectious disease worldwide. Currently we are combating twelve major infectious diseases with its range of marketed vaccines in the paediatric, travel and endemic and respiratory fields.
Headquartered in Leiden, The Netherlands, Crucell currently employs more than 1200 people and has subsidiaries in Switzerland, Spain, Sweden, Italy, Korea the United Kingdom and the United States. Crucell N.V. is listed on Euronext and NASDAQ (CRXL) and the SWX Swiss Exchange (CRX). At Crucell, we're bringing innovation to global health.
Read more about the Runbook solutions here
